The value of combining two cancer markers PROGRP, NSE serum in diagnosis of small cell lung cancer at the National Lung Hospital
Main Article Content
Abstract
The study was conducted to assess the value of the distribution of 2 markers (ProGRP and NSE) serum in the diagnosis of small cell lung cancer (SCLC) at the National Lung Hospital from May 2024 to May 2025: 60 inpatients with small cell lung cancer (SCLC patient group), 60 inpatients with non small cell lung cancer (NSCLC patient group) and 60 healthy individuals (control group) were selected. Results: Concentrations median of ProGRP, NSE in the patient group were highest by 418.6 and 64.38 pg/ml, with p < 0.001. The cutoff point, sensitivity, specificity and AUC for ProGRP, NSE in the diagnosis of SCLC were 57.6; 14.31 pg/ml; 88.3%; 88.3 and 93.3%; 83.3% and 0.929; 0.929. Combining the 2 markers in the diagnosis of SCLC showed sensitivity and specificity of 85.5% and 95.5% with AUC 0.912. In the differential diagnosis of SCLC from NSCLC, combined markers showed sensitivity and specificity of 83.5% and 93.5% with AUC of 0.902.
Article Details
Keywords
Combination, PROGRP, NSE SERUM, DIAGNOSIS OF SCLC, National Lung Hospital
References
2. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263. doi:10.3322/caac.21834.
3. Trường Đại học Y Hà Nội. Hóa sinh lâm sàng. Nhà Xuất bản Y học; 2013.
4. Bộ Y tế. Quyết định về việc ban hành tài liệu “Hướng dẫn quy trình kỹ thuật chuyên ngành Hóa sinh.” Published online 2014. Số: 320 /QĐ-BYT.
5. GAO Jie, et al. Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types. J South Med Univ. 2022, 42(6): 886-891.
6. Bộ Y tế. Ung thư phổi tế bào nhỏ. Hướng dẫn chẩn đoán và điều trị một số bệnh ung bướu. Quyết định số 1514/QĐ-BYT ngày 01 tháng 04 năm 2020 của Bộ trưởng Bộ Y tế. Nhà Xuất bản Y học Hà Nội - 2020. p242-254.
7. Hyung-Joo Oh, et al. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis. 2016;8(9):2530-2537. doi: 10.21037/jtd.2016.08.72.
8. Ming Li, et al. Decline in serum progastrinreleasing peptide predicts the response of patients with small cell lung cancer to chemotherapy. Oncology Letters. 2020;20:301. DOI: 10.3892/ol.2020.12164.
9. Ping Wang, et al. Diagnostic value and therapeutic efficacy of serum levels of pro-gastrin-releasing peptide precursor (progrp) and neuron-specific enolase (nse) in patients with lung cancer. J Med Biochem. 2025;44:945-954. DOI: 10.5937/jomb0-50852.
10. Chen S, et al. Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer. Published online January 11, 2022. doi:10.21203/rs.3.rs-1145818/v2.
11. Yan PENG, et al. Utility of NSE, ProGRP and LDH in Diagnosis and Treatment in Patients with Small Cell Lung Cancer. Chin J Lung Cancer. September 2016, Vol.19, No.9.
12. Mao CY, Kai XU, Lai YY, et al. Systematic review of value of combined detection of ProGRP/NSE in diagnosis of small cell lung cancer patients. Clinical Research. 2015, 15(4): 452-456.
13. Li Li, et al. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer. J Clin Lab Anal. 2023;37:e24865. https://doi.org/10.1002/jcla.24865.